国产一区二区三区久久精品-国产一区二区三区久久-国产一区二区三区精品视频-国产一区二区三区国产精品-国产一区二区三区高清-国产一区二区三区成人久久片

產品詳情
  • 產品名稱:Anti-PCP4抗體

  • 產品型號:腦特異性多肽蛋白19抗體
  • 產品廠商:KALANG
  • 產品文檔:
你添加了1件商品 查看購物車
簡單介紹:
Anti-PCP4抗體產品質量穩定,實驗效果明顯,貨期快,價格優惠,歡迎垂詢訂購!我公司長期供應**組化抗體、WB抗體、**組化試劑盒和抗體試驗所需全部相關試劑、熒光標記抗體、單克隆抗體、多克隆抗體、各種標記的二抗IgG/IgM/IgD/IgA等科研實驗抗體。Anti-PCP4抗體用于**組化實驗,WB實驗,相應的標記抗體有HRP標記抗體,FITC標記,BIO等。
詳情介紹:
Rabbit  Anti-PCP4
Cat. Number:
Anti-PCP4抗體KL-11326R
Quantity size:
0.2ml
Concentration:
1mg/ml   Buffer = 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Background:
PCP-4 is a calmodulin (CaM) regulatory protein that is highly expressed in neuronal cells. Through its IQ motif, PCP-4 mediates both the calcium-dependent binding properties of CaM and the rates of association and dissociation ofAnti-PCP4抗體 calcium from the C-terminal domain of CaM. The IQ motif contains a serine residue which can be phosphorylated by all isoforms of protein kinase C (PKC). PCP-4 is implicated in uterine leiomyomas, as well as in neurodegenerative disorders such as Alzheimer’s disease and Huntington's disease. Additionally, overexpression of PCP-4 is thought to play a role in cerebellar hypoplasia, a key feature of Down syndrome.
Also known as:
Brain specific antigen PCP 4; Brain specific polypeptide PEP 19; Brain specific polypeptide PEP19; PEP19; Purkinje cell protein 4; Anti-PCP4抗體PCP-4; PCP4_HUMAN; PEP-19.
Specificity:
Rabbit Polyclonal IgG, affinity purified by Protein A.
Reacts with: Human, Mouse, Rat, Anti-PCP4抗體Cow, Sheep, .
Immunogen: KLH conjugated synthetic peptide derived from human PCP4.
Predicted Molecular Weight: 7kDa.
Storage:
Shipped at 4℃, Store at -20℃ (Avoid repeated freeze/thaw cycles).
Application:
ELISA=1:500-1000  IHC-P=1:100-500  IHC-F=1:100-500  ICC=1:100-500  IF=1:100-500   
Not yet tested in other applications. Anti-PCP4抗體
Optimal working dilutions must be determined by the end user.

標題:
內容:
聯系人:
聯系電話:
Email:
公司名稱:
聯系地址:
 
 
注:1.可以使用快捷鍵Alt+S或Ctrl+Enter發送信息!
2.如有必要,請您留下您的詳細聯系方式!

滬公網安備 31011702004399號

主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |